Kanagaratnam Sivalingam, MD
Geriatric Medicine · Lancaster, CANPI 1578578365
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by Boehringer Ingelheim at 24.3% of the total. Reporting peaked in 2021 at $1,810 and has fallen 80.6% since, to $352 in 2025. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Amgen$777
- Merck$584
- GSK$477
- AbbVie$302
- Johnson & Johnson$281
- plus $2K from 33 others
Across 2,187 payments — averaging $1104.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.3M
- Novo Nordisk AS$1.1M
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Chiesi USA, Inc.$6K
- GSK$3K
- Boehringer Ingelheim$392
- plus $372 from 1 others
What the payments were for
- Food & beverage$6,393100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 71 | $1,554 |
| Amgen(2 entities) | 42 | $777 |
| Merck | 21 | $584 |
| GSK | 32 | $477 |
| AbbVie(2 entities) | 18 | $302 |
| Johnson & Johnson | 4 | $281 |
| Irhythm Technologies, Inc. | 20 | $272 |
| Novo Nordisk | 11 | $213 |
| Novartis | 12 | $202 |
| Bayer | 8 | $167 |
| Mylan Specialty L.p. | 7 | $157 |
| Lilly USA, LLC | 6 | $149 |
| Abbott | 8 | $146 |
| Arbor Pharmaceuticals, Inc. | 8 | $137 |
| AstraZeneca | 8 | $133 |
| Mannkind Corporation | 5 | $96 |
| Redhill Biopharma Inc. | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Ironwood Pharmaceuticals, Inc | 2 | $53 |
| Pfizer | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $36 |
| Dexcom, Inc. | 1 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| Radius Health, Inc. | 1 | $26 |
| Exact Sciences | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,393 in reported general payments places this provider in the 90th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 16 | $47,224 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $34,402 |
| XareltoRivaroxaban | 34 | $28,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $27,065 |
| JardianceEmpagliflozin | 22 | $24,621 |
| OzempicSemaglutide | 17 | $23,751 |
| EliquisApixaban | 22 | $20,846 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $16,112 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $14,988 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $11,476 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $5,441 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $4,663 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $4,212 |
| Rosuvastatin Calcium | 115 | $3,028 |
| Atorvastatin Calcium | 171 | $2,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $302 | $47,22416 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $1,554 | $39,60950 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $477 | $38,54148 claims |
| Johnson & JohnsonXarelto | $281 | $28,50434 claims |
| Novo NordiskOzempic | $213 | $23,75117 claims |
| PfizerEliquis | $48 | $20,84622 claims |
| AstraZenecaBreztri Aerosphere | $133 | $16,11217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Lancaster
- Vincent HoLancaster$32K
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
- Douglas ZhangSan Leandro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.